Assenagon Asset Management S.A. Has $3.18 Million Stock Holdings in OraSure Technologies, Inc. (NASDAQ:OSUR)

Assenagon Asset Management S.A. trimmed its position in shares of OraSure Technologies, Inc. (NASDAQ:OSURFree Report) by 22.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 387,535 shares of the medical instruments supplier’s stock after selling 109,261 shares during the quarter. Assenagon Asset Management S.A. owned approximately 0.53% of OraSure Technologies worth $3,178,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Cerity Partners LLC acquired a new stake in shares of OraSure Technologies during the first quarter valued at about $378,000. 1832 Asset Management L.P. acquired a new stake in shares of OraSure Technologies during the first quarter valued at about $40,000. Commonwealth Equity Services LLC acquired a new stake in shares of OraSure Technologies during the first quarter valued at about $63,000. FMR LLC raised its position in shares of OraSure Technologies by 249.6% during the second quarter. FMR LLC now owns 10,687 shares of the medical instruments supplier’s stock worth $29,000 after acquiring an additional 7,630 shares during the last quarter. Finally, Private Advisor Group LLC bought a new position in shares of OraSure Technologies during the first quarter worth about $68,000. 93.50% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, Citigroup raised their price objective on OraSure Technologies from $7.00 to $9.00 and gave the stock a “buy” rating in a research report on Monday, December 11th.

Check Out Our Latest Stock Analysis on OSUR

OraSure Technologies Price Performance

Shares of OSUR opened at $6.01 on Wednesday. OraSure Technologies, Inc. has a 1 year low of $4.38 and a 1 year high of $8.45. The company has a market capitalization of $459.83 million, a price-to-earnings ratio of 8.35 and a beta of 0.15. The business has a 50-day moving average of $6.96 and a 200-day moving average of $6.83.

OraSure Technologies (NASDAQ:OSURGet Free Report) last issued its quarterly earnings data on Tuesday, February 27th. The medical instruments supplier reported $0.22 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.13 by $0.09. The company had revenue of $75.88 million during the quarter, compared to the consensus estimate of $74.13 million. OraSure Technologies had a return on equity of 14.50% and a net margin of 13.23%. The firm’s revenue was down 38.3% compared to the same quarter last year. During the same period last year, the company earned $0.21 earnings per share. As a group, sell-side analysts anticipate that OraSure Technologies, Inc. will post -0.11 EPS for the current year.

About OraSure Technologies

(Free Report)

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.

Read More

Institutional Ownership by Quarter for OraSure Technologies (NASDAQ:OSUR)

Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.